DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN United Kingdom - Great Britain ONLY.
Information about the Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)
This medicinal product has been given conditional marketing authorisation for Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA). This conditional marketing authorisation allows Nuvaxovid to be used for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 years of age and older.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Report an Adverse Event (AE)
If you are concerned about an adverse event, it should be reported on a Yellow Card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card on the Google Play or Apple Store. When reporting, please include the vaccine brand and batch/Lot number if available.
Alternatively, adverse events of concern in association with Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted), can be reported to Novavax Pharmacovigillance at +44 203 5141838 or via the Novavax Adverse Event Reporting Form.
Please do not report the same adverse event(s) to both systems as all reports will be shared between Novavax and MHRA (in anonymised form) and dual reporting will create unnecessary duplicates.
Contact Us
Tel: +44 203 5141838
09:00 - 17:00
Monday - Friday